biocryst.com (BCRX) Value Adjusted for Debt and Cash
BioCryst (BCRX) generates revenue through the commercialization of advanced treatments for rare pathologies and grants for developing antiviral formulas. The stock's price history reflects a current Separate Enterprise Value of 2497.21. High profitability is driven by the monopoly status of the drug ORLADEYO, which replaced injections with a convenient tablet format. Growing sales of the oral medication stabilize the operating model, enabling the efficient funding of new product line expansions.
BioCryst (BCRX) - metric breakdowns and financial figures
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Comprehensive company analysis:BioCryst Pharmaceuticals, Inc. (BCRX)
Conservative capital demands absolute transparency of the capital structure to assess business resilience. This metric determines the total cost of acquiring an asset by summing market capitalization and debt obligations minus cash and cash equivalents. For BioCryst (BCRX), this calculation accounts for the development costs of orphan drugs and antiviral medications. The enterprise value indicator reflects the company's actual financial weight. However, the excessive smoothness of this chart may mask impending volatility.
Competitor analysis for BioCryst
argenx N.V. - Real Price to Acquire Entire Company|Total Company Value BioNTech Group (BNTX)|Abivax Pharma (ABVX) - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company ADMA Biologics|PTGX (protagonist-inc.com) - Business Value|Total Company Value Immunovant IMVT|Full Business Value Kiniksa Pharmaceuticals, Ltd.|Grifols Group (GRFS) - Enterprise Value|Value Adjusted for Debt and Cash Adaptive Biotechnologies Inc. (ADPT)|Enterprise Value CLDX (Celldex Therapeutics)|auriniapharma.com - Enterprise Value|Total Company Value Vera Therapeutics (VERA)|DNTH: Value Adjusted for Debt and Cash|PHVS (Pharvaris Corp) - Total Company Value|AbCellera Biologics Inc. (ABCL) - Real Price to Acquire Entire Company|TRML (Tourmaline Bio, Inc.) - Enterprise Value|Enterprise Value precigen.com (PGEN)|Pharming Group (PHAR) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Nektar Therapeutics Inc (NKTR)|Enterprise Value UPB|Zenas Corp - Company Buyout Price|IMNM: Total Company Value|GOSS: Real Price to Acquire Entire Company|KALV (KalVista Pharmaceuticals, Inc.) - Total Company Value|Real Price to Acquire Entire Company Septerna, Inc.|PVLA (Pieris Pharmaceuticals Inc) - Real Price to Acquire Entire Company|Enterprise Value SVRA|Total Company Value Rigel Pharmaceuticals RIGL|Business Value anaptysbio.com (ANAB)|ATXS: Enterprise Value|Total Enterprise Value enGene Holdings Inc ENGN|RAPT - Enterprise Value|JBIO - Total Company Value|Aclaris Therapeutics - Enterprise Value|KYTX (kyvernatx.com) - Company Buyout Price|Total Company Value TLSA (Tiziana Life Sciences Ltd)|Total Enterprise Value Cabaletta Bio Inc.|Enterprise Value VTYX (Ventyx Bio)|Real Price to Acquire Entire Company THTX (Theratechnologies, Inc)|Total Company Value Avalo Therapeutics, Inc|ELDN - Value Adjusted for Debt and Cash|AGEN (Agenus Inc.) - Real Price to Acquire Entire Company|CLYM: Total Enterprise Value|Zura Bio - Total Company Value|Company Buyout Price aTyr Pharmaceuticals|Adagene Inc (ADAG) - Real Price to Acquire Entire Company|Aggregate Business Value Ikena Oncology, Inc.|Enterprise Value Shattuck Labs, Inc. (STTK)|Total Company Value equilliumbio.com (EQ)|Connect Biopharma Holdings Limited - Enterprise Value|Immunic Therapeutics - Real Price to Acquire Entire Company|Total Company Value Atara Biotherapeutics Inc (ATRA)|InflaRx N.V. (IFRX) - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company X4 Pharmaceuticals, Inc.|ACET (Adicet Bio, Inc.) - Business Value|Total Company Value Celularity Inc CELU|Full Business Value INmune Bio Corporation|Barinthus Biotherapeutics (BRNS) - Enterprise Value|Value Adjusted for Debt and Cash kezarlifesciences.com (KZR)|Enterprise Value SABS (SAB Biotherapeutics, Inc.)|Akari Therapeutics PLC - Enterprise Value|Total Company Value Enlivex Therapeutics, Ltd. (ENLV)|QTTB: Value Adjusted for Debt and Cash|GOVX (GeoVax Labs, Inc.) - Total Company Value|edesabiotech.com (EDSA) - Real Price to Acquire Entire Company|IBIO (iBio) - Enterprise Value|Enterprise Value Carisma Tx (CARM)|XTL Biopharmaceuticals, Ltd. (XTLB) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash boltbio.com (BOLT)|Enterprise Value HCWB|Aptevo Therapeutics, Inc. - Company Buyout Price|AIM: Total Company Value|ADTX: Real Price to Acquire Entire Company|GRI (GRI Bio Corp) - Total Company Value|Real Price to Acquire Entire Company XORTX Corp|HIND (Vyome Holdings Inc) - Real Price to Acquire Entire Company|Enterprise Value REVB|Total Company Value Indaptus Therapeutics, Inc. INDP|Business Value Scinai Immunotherapeutics Ltd (SCNI)|CALI: Enterprise Value|Total Enterprise Value Affimed NV AFMD|ALLK - Enterprise Value|HOOK - Total Company Value|igmbio.com - Enterprise Value|ITOS (iTeos Therapeutics Inc) - Company Buyout Price|Total Company Value OCEA (Ocean Bio)|Total Enterprise Value TC BioPharm Ltd|Enterprise Value THRD (Third Harmonic Bio)